

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patent Owner

Case IPR2018-01427
Patent 8,597,649 B2

DECLARATION OF DR. MICHEL D. FERRARI, M.D., PH.D.

Inter Partes Review of USPN 8,597,649
Declaration of Michel D. Ferrari, M.D., Ph.D. (EX2141)

TABLE OF CONTENTS

I.	Introduction.....	1	
II.	My Background and Qualifications.....	2	
III.	Summary of Opinions.....	5	
IV.	List of Documents I Considered in Formulating My Opinions	6	
V.	Person of Ordinary Skill in the Art.....	12	
VI.	The '649 Patent Claims	13	
VII.	My Understanding of Obviousness	14	
VIII.	Before November 2005, the field was focused on treating acute migraine with small molecule therapeutics with short half-lives	15	
IX.	Dr. Charles and Dr. Vasserot ignored the potentially life-threatening side effects of long-term antagonism of CGRP's normal function.....	19	
	A.	Problems in the vascular system can lead to life-threatening situations....	20
	B.	Because of CGRP's potent vasodilatory properties, a POSA would have expected that sequestering CGRP would risk serious negative consequences to a patient's vascular health	23
	1.	CGRP plays important protective roles in maintaining vascular health....	25
	2.	A POSA would have expected that sequestering CGRP would risk serious ischemic episodes.....	28
	3.	A POSA would have expected that sequestering CGRP would lead to high blood pressure and its associated risk of heart disease and stroke	32
	C.	Anti-CGRP antibodies would have presented an even greater risk for migraineurs because of an established comorbidity of migraine with stroke and cardiac infarcs.....	37
	D.	Tan 1995 did not demonstrate that a full length antibody could be safe or effective for clinical use in patients.....	39

*Inter Partes Review of USPN 8,597,649
Declaration of Michel D. Ferrari, M.D., Ph.D. (EX2141)*

E.	Lassen did not demonstrate that an anti-CGRP antibody could be safe or effective for clinical use in patients.....	42
X.	Experiments with BIBN4096BS had not demonstrated that anti-CGRP antibodies were suitable for or safe in human patients.....	43
XI.	Contrary to Dr. Charles’s and Dr. Vasserot’s assertions, CGRP antibodies were not known treatment options for CGRP-mediated diseases prior to November 14, 2005.....	46
XII.	Dr. Charles’s and Dr. Vasserot’s arguments are particularly flawed with respect to claims 8 and 9.....	51
XIII.	Anti-CGRP antibodies demonstrated unexpectedly superior results	53
XIV.	Humanized anti-CGRP antibodies faced industry skepticism	55

..

***Inter Partes Review of USPN 8,597,649
Declaration of Michel D. Ferrari, M.D., Ph.D. (EX2141)***

I, Michel D. Ferrari, M.D., Ph.D., hereby declare as follows.

I. Introduction

1. I have been retained as an expert witness on behalf of Teva Pharmaceuticals International GMBH (“Teva”) for the above-captioned *inter partes* review (IPR). I am being compensated for my time in connection with this IPR at my standard consulting rate, but my compensation is not contingent upon my opinions or the outcome of this or any other proceeding.

2. I understand that this Declaration accompanies Teva’s response to an IPR petition involving U.S. Patent No. 8,597,649 (“the ’649 patent”) (EX1001). I understand that the petition was filed by Eli Lilly and Company (“Lilly”). I understand that the ’649 patent resulted from U.S. Patent Application No. 13/870,871 (“the ’871 application”). I understand that the ’871 application is a continuation application that relates to a series of previous applications. I also understand that the earliest possible priority date of the ’649 patent is the November 14, 2005 filing date of U.S. Patent Application No. 60/736,623, and I refer to this date throughout this declaration. The ’649 patent issued on December 3, 2013.

3. In preparing this Declaration, I have reviewed the ’649 patent and each of the documents cited herein from the perspective of a person of ordinary

***Inter Partes Review of USPN 8,597,649
Declaration of Michel D. Ferrari, M.D., Ph.D. (EX2141)***

skill in the art, in light of general knowledge in the art before November 14, 2005.

In formulating my opinions, I have relied upon my experience, education, and knowledge in the relevant art. In formulating my opinions, I have also considered the viewpoint of a person of ordinary skill in the art (“POSA”) (*i.e.*, a person of ordinary skill in the field of the ’649 patent, as defined further below in Section V) prior to November 14, 2005.

II. My Background and Qualifications

4. My qualifications and credentials are more fully set forth in my *curriculum vitae*, provided as EX2142. I am an expert in the field of clinical neurology, and have been since approximately 1985. I have been actively working in the field of neurology, with a focus on migraine, since 1980, and have gained significant experience in this field while both performing clinical research and treating patients since I graduated from medical school.

5. I studied medicine at the University of Leiden and received my Doctor of Medicine Degree in 1980. I subsequently decided to specialize in Neurology and Neuroscience and received specialty certificates in Neurology and Clinical Neurophysiology in 1985. I was awarded a Ph.D. *cum laude* in 1992 and the title of my thesis was “Serotonin and Migraine,”

6. I have dedicated much of my career to the study of migraine and other primary headaches and the focus of my research has been aimed at unravelling the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.